Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells
- 1 March 2010
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 23 (9) , 914-923
Abstract
During kidney allograft rejection, CXC chemokine ligand 10 (CXCL10)-CXC chemokine receptor 3 (CXCR3) trafficking between peripheral blood and tissues initiates alloresponse and perpetuates a self-inflammatory loop; thus, CXCL10-CXCR3 axis could represent a pharmacologic target. In this perspective, immunosuppressors targeting graft-resident cells, beside immune cells, could be very advantageous. Vitamin D receptor (VDR) agonists exhibit considerable immunomodulatory properties. This study aimed to investigate whether elocalcitol and BXL-01-0029 could decrease the expression of CXCL10 in activated renal tubular cells in vitro and thus be useful in kidney allograft rejection treatment. Experiments were performed in human tubular renal cells stimulated with interferon-gamma + tumor necrosis factor-alpha with and without VDR agonists, tacrolimus, sirolimus, hydrocortisone, methylprednisolone, cyclosporin A and mycophenolate mofetil. CXCL10 protein secretion and gene expression were measured by ELISA and by quantitative PCR. Specific inhibitors were used to investigate intracellular pathways involved in tubular cells activation. For IC(50) determination and comparison, dose-response curves with VDR agonists, tacrolimus and mycophenolic acid were performed. Elocalcitol and BXL-01-0029 inhibited CXCL10 secretion by renal cells, without affecting cell viability, while almost all the immunosuppressors were found to be ineffective, except for tacrolimus and mycophenolate mofetil. BXL-01-0029 was the most potent drug and, notably, it was found to be capable of allowing reduction in tacrolimus-inhibitory doses. Our data suggest that BXL-01-0029 could potentially be a dose-reducing agent for conventional immunosuppressors in kidney rejection management.Keywords
This publication has 68 references indexed in Scilit:
- Compartment-Specific Expression and Function of the Chemokine IP-10/CXCL10 in a Model of Renal Endothelial Microvascular InjuryJournal of the American Society of Nephrology, 2006
- Inhibition of Acute and Chronic Allograft Rejection in Mouse Models by BXL-628, a Nonhypercalcemic Vitamin D Receptor AgonistTransplantation, 2005
- High CXCL10 Expression in Rejected Kidneys and Predictive Role of Pretransplant Serum CXCL10 for Acute Rejection And Chronic Allograft NephropathyTransplantation, 2005
- High Pretransplant Serum Levels of CXCL10/IP-10 Are Related to Increased Risk of Renal Allograft FailureAmerican Journal of Transplantation, 2004
- Allergic humans are hypo‐responsive to CXCR3 chemokines in a Th1 immunity‐promoting loopThe FASEB Journal, 2003
- Chemokines and chemokine receptors are involved in the resolution or progression of renal diseaseKidney International, 2003
- Regulatory T Cells Induced by 1α,25-Dihydroxyvitamin D3 and Mycophenolate Mofetil Treatment Mediate Transplantation ToleranceThe Journal of Immunology, 2001
- Expression of chemokines and chemokine receptors during human renal transplant rejectionAmerican Journal of Kidney Diseases, 2001
- ANALOGS OF 1,25-DIHYDROXYVITAMIN D 3 AS DOSE-REDUCING AGENTS FOR CLASSICAL IMMUNOSUPPRESSANTS12Transplantation, 2000
- Chemokines, Chemokine Receptors, and Renal DiseaseJournal of the American Society of Nephrology, 2000